ABSTRACT
Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer (SCLC ) . Methods PubMed ,Embase ,the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC .A Meta-analysis was performed over the published clinical trials .The efficacy and safety of amrubicin were evaluated based on overall survival (OS) ,progression-free survival (PFS) ,overall response rate (ORR) and toxicity .Results Our anal-ysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group [RR 1 .72 ,95% CI (1 .39 , 2.14) ,P=0 .000] ,the OS ,PFS and toxicity were no-inferior to the control group(P=0 .405 ,P=0.456) .Conclusion Am-rubicin can be considered as a good second-line treatment for relapsed SCLC .